Table 1.
Patients’ Clinical Characteristics
| Characteristic | When CNS involvement was identified | Total | ||
|---|---|---|---|---|
| Group A (at RMS diagnosis) |
Group B
(on RMS progression) |
Group C
(at RMS relapse) |
||
| Sex | ||||
| Male | 3 | 18 | 4 | 25 |
| Female | 3 | 6 | 5 | 14 |
| Age | ||||
| <1 yrs | 0 | 1 | 0 | 1 |
| 1–3 yrs | 1 | 5 | 6 | 12 |
| 3–10 yrs | 3 | 12 | 2 | 17 |
| >10 yrs | 2 | 6 | 1 | 9 |
| Primary site | ||||
| Orbit | 0 | 0 | 0 | 0 |
| Head and neck | 0 | 1 | 0 | 1 |
| Parameningeal | 3 | 17 | 7 | 27 |
| Genitourinary tract | 1 | 1 | 0 | 2 |
| Extremities | 1 | 4 | 2 | 7 |
| Other sites | 0 | 1 | 0 | 1 |
| Unknown | 1 | 0 | 0 | 1 |
| Histology | ||||
| Alveolar | 2 | 10 | 4 | 16 |
| Embryonal | 3 | 14 | 4 | 21 |
| Not otherwise specified | 1 | 0 | 1 | 2 |
| T Classification | ||||
| T1 | 0 | 4 | 3 | 7 |
| T2 | 5 | 20 | 6 | 31 |
| Missing | 1 | 0 | 0 | 1 |
| N Classification | ||||
| N0 | 3 | 11 | 6 | 20 |
| N1 | 3 | 12 | 3 | 18 |
| Missing | 0 | 1 | 0 | 1 |
| Tumor size | ||||
| <5 cm | 2 | 3 | 2 | 7 |
| >5 cm | 3 | 18 | 7 | 28 |
| Missing | 1 | 3 | 0 | 4 |
| IRS Group | ||||
| I | 0 | 0 | 1 | 1 |
| II | 0 | 1 | 0 | 1 |
| III | 1 | 14 | 5 | 20 |
| IV | 5 | 9 | 3 | 17 |
| CNS involvement | ||||
| Metastasis | 2 | 3 | 2 | 7 |
| Meningeal spread | 4 | 21 | 7 | 32 |
| Total | 6 | 24 | 9 | 39 |
Abbreviations: CNS, central nervous system; IRS, intergroup rhabdomyosarcoma study; NOS, not otherwise specified.